Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Feb;17(2):737-47.
doi: 10.1007/s10461-012-0333-8.

Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women

Alexandra M Minnis  1 , Sharavi Gandham, Barbra A Richardson, Vijayanand Guddera, Beatrice A Chen, Robert Salata, Clemensia Nakabiito, Craig Hoesley, Jessica Justman, Lydia Soto-Torres, Karen Patterson, Kailazarid Gomez, Craig W Hendrix
Affiliations
Clinical Trial

Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women

Alexandra M Minnis et al. AIDS Behav. 2013 Feb.

Abstract

We compared adherence to and acceptability of daily topical and oral formulations of tenofovir (TFV) used as pre-exposure prophylaxis (PrEP) for HIV prevention among women in South Africa, Uganda and the United States. 144 sexually active, HIV-uninfected women participated in a cross-over study of three regimens: oral tablet, vaginal gel, or both. We tested for differences in adherence and evaluated product acceptability. Self-reported adherence for all regimens was high (94 %), but serum TFV concentrations indicated only 64 % of participants used tablets consistently. Most women in the U.S. (72 %) favored tablets over gel; while preferences varied at the African sites (42 % preferred gel and 40 % tablets). Findings indicate a role for oral and vaginal PrEP formulations and highlight the importance of integrating pharmacokinetics-based adherence assessment in future trials. Biomedical HIV prevention interventions should consider geographic and cultural experience with product formulations, partner involvement, and sexual health benefits that ultimately influence use.

Trial registration: ClinicalTrials.gov NCT00592124.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MTN 001 – Phase 2 Adherence and Pharmacokinetic Study of Oral and Vaginal Preparations of Tenofovir
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13–F19. Epub 2012/02/16. - PubMed
    1. Kashuba AD, Patterson KB, Dumond JB, Cohen MS. Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet. 2012;379(9835):2409–2411. Epub 2011/12/14. - PMC - PubMed
    1. Cohen M, Baden L. Preexposure prophylaxis for HIV--where do we go from here? N Engl J Med. 2012;367(5):459–461. - PubMed
    1. Grady D. FDA advisory panel backs preventive use of HIV drug. New York Times. 2012 May 10;:D5.
    1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–1174. Epub 2010/07/21. - PMC - PubMed

Publication types

MeSH terms

Associated data